Skip to main content
Midas Edge

PAVmed Inc.

For the period ended Dec 31, 2025. Filed Mar 27, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 27, 2026

PAVM$1.56-4.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Changes in Stockholders’ Equity (Deficit)

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’** EQUITY (DEFICIT)**

for the YEAR ENDED December 31, 2025

​ · ​ · PAVmed Inc. Stockholders’ Equity (Deficit) · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Series B · ​ · ​ · Series C · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Convertible · ​ · ​ · Convertible · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · ​ · ​ · ​ · ​ · ​ · Non · ​ · ​ · ​ · ​ · ​
​ · ​ · Preferred Stock · ​ · ​ · Preferred Stock · ​ · ​ · Common Stock · ​ · ​ · Paid-In · ​ · ​ · Accumulated · ​ · ​ · controlling · ​ · ​ · ​ · ​ · ​
​ · ​ · Shares · ​ · ​ · Amount · ​ · ​ · Shares · ​ · ​ · Amount · ​ · ​ · Shares · ​ · ​ · Amount · ​ · ​ · Capital · ​ · ​ · Deficit · ​ · ​ · Interest · ​ · ​ · Total · ​
Balance - December 31, 2024​​1,412,865​​$3,316​​​—​​$—​​​373,300​​$1​​$249,153​​$(254,965)​$(4,538)​$(7,033)
Dividends declared - Series B Convertible Preferred Stock​​116,524​​​349​​​—​​​—​​​—​​​—​​​—​​​(349)​​—​​​—​
Issue common stock - PAVM ATM Facility​​—​​​—​​​—​​​—​​​40,553​​​—​​​841​​​—​​​—​​​841​
Vest - restricted stock awards​​—​​​—​​​—​​​—​​​8,752​​​—​​​—​​​—​​​—​​​—​
Conversions - Senior Secured Convertible Note​​—​​​—​​​—​​​—​​​13,377​​​—​​​260​​​—​​​—​​​260​
Impact of subsidiary equity transactions​​—​​​—​​​—​​​—​​​—​​​—​​​8,412​​​—​​​(8,412)​​—​
Issuance - vendor service agreement​​—​​​—​​​—​​​—​​​5,081​​​—​​​103​​​—​​​402​​​505​
Issuance - common stock private placement offering with pre-funded warrants and Veris Health common stock issuance, net of issuance costs​​—​​​—​​​—​​​—​​​85,812​​​—​​​1,422​​​—​​​948​​​2,370​
Issuance - common stock - subsidiary, net of issuance costs​​—​​​—​​​—​​​—​​​—​​​—​​​—​​​—​​​2,488​​​2,488​
Issuance through debt exchange - Series C Convertible Preferred Stock, net of financing fees​​—​​​—​​​22,347​​​22,347​​​—​​​—​​​(109)​​—​​​—​​​22,238​
Issuance through unsecured debt obligation cancellation - Series C Convertible Preferred Stock​​—​​​—​​​2,653​​​2,653​​​—​​​—​​​—​​​—​​​—​​​2,653​
Conversions - Series C Convertible Preferred Stock​​—​​​—​​​(4,352)​​(4,510)​​375,834​​​—​​​4,510​​​—​​​—​​​—​
Exchange Series C Convertible Preferred Stock to Senior Secured Convertible Debt​​—​​​—​​​(1,191)​​(1,260)​​—​​​—​​​—​​​—​​​—​​​(1,260)
Dividends earned - Series C Convertible Preferred Stock​​—​​​—​​​—​​​1,783​​​—​​​—​​​—​​​(1,783)​​—​​​—​
Deemed dividend on Series C Convertible Preferred Stock​​—​​​—​​​—​​​—​​​—​​​—​​​2,035​​​(2,035)​​—​​​—​
Exercise Pre-funded warrants​​—​​​—​​​—​​​—​​​25,225​​​—​​​—​​​—​​​—​​​—​
Stock-based compensation - PAVmed Inc.​​—​​​—​​​—​​​—​​​—​​​—​​​1,392​​​—​​​—​​​1,392​
Stock-based compensation - subsidiaries​​—​​​—​​​—​​​—​​​—​​​—​​​—​​​—​​​315​​​315​
Net income (loss)​​—​​​—​​​—​​​—​​​—​​​—​​​—​​​401​​​(2,870)​​(2,469)
Balance - December 31, 2025​​1,529,389​​$3,665​​​19,457​​$21,013​​​927,934​​$1​​$268,019​​$(258,731)​$(11,667)​$22,300​
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.